Aspergillosis: Emerging risk groups in critically ill patients
- PMID: 34677613
- DOI: 10.1093/mmy/myab064
Aspergillosis: Emerging risk groups in critically ill patients
Abstract
Information on invasive aspergillosis (IA) and other invasive filamentous fungal infections is limited in non-neutropenic patients admitted to the intensive care unit (ICU) and presenting with no classic IA risk factors. This review is based on the critical appraisal of relevant literature, on the authors' own experience and on discussions that took place at a consensus conference. It aims to review risk factors favoring aspergillosis in ICU patients, with a special emphasis on often overlooked or neglected conditions. In the ICU patients, corticosteroid use to treat underlying conditions such as chronic obstructive pulmonary disease (COPD), sepsis, or severe COVID-19, represents a cardinal risk factor for IA. Important additional host risk factors are COPD, decompensated cirrhosis, liver failure, and severe viral pneumonia (influenza, COVID-19). Clinical observations indicate that patients admitted to the ICU because of sepsis or acute respiratory distress syndrome are more likely to develop probable or proven IA, suggesting that sepsis could also be a possible direct risk factor for IA, as could small molecule inhibitors used in oncology. There are no recommendations for prophylaxis in ICU patients; posaconazole mold-active primary prophylaxis is used in some centers according to guidelines for other patient populations and IA treatment in critically ill patients is basically the same as in other patient populations. A combined evaluation of clinical signs and imaging, classical biomarkers such as the GM assay, and fungal cultures examination, remain the best option to assess response to treatment.
Lay summary: The use of corticosteroids and the presence of co-morbidities such as chronic obstructive pulmonary disease, acute or chronic advanced liver disease, or severe viral pneumonia caused by influenza or Covid-19, may increase the risk of invasive aspergillosis in intensive care unit patients.
Keywords: COVID-19; chronic obstructive pulmonary disease; cirrhosis; influenza; intensive care unit; invasive aspergillosis; sepsis; viral pneumonia.
© The Author(s) 2021. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.
Similar articles
-
Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/ MSG and ICU criteria.BMC Infect Dis. 2017 Mar 14;17(1):209. doi: 10.1186/s12879-017-2307-y. BMC Infect Dis. 2017. PMID: 28292284 Free PMC article.
-
COVID-19 associated Pulmonary Aspergillosis in Patients Admitted to the Intensive Care Unit: Impact of Antifungal Prophylaxis.Mycopathologia. 2024 Jan 13;189(1):3. doi: 10.1007/s11046-023-00809-y. Mycopathologia. 2024. PMID: 38217742 Free PMC article.
-
Invasive pulmonary aspergillosis in the ICU: tale of a broadening risk profile.Curr Opin Crit Care. 2023 Oct 1;29(5):463-469. doi: 10.1097/MCC.0000000000001070. Epub 2023 Jul 27. Curr Opin Crit Care. 2023. PMID: 37641513 Review.
-
Intensive care management of influenza-associated pulmonary aspergillosis.Clin Microbiol Infect. 2019 Dec;25(12):1501-1509. doi: 10.1016/j.cmi.2019.04.031. Epub 2019 May 16. Clin Microbiol Infect. 2019. PMID: 31102782 Review.
-
Invasive aspergillosis in critically ill patients without malignancy.Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5. doi: 10.1164/rccm.200401-093OC. Epub 2004 Jun 30. Am J Respir Crit Care Med. 2004. PMID: 15229094
Cited by
-
A scoring system based on novel biomarkers and clinical risk factors to predict invasive candidiasis in immunocompetent critically ill patients.Front Microbiol. 2023 Mar 9;14:1097574. doi: 10.3389/fmicb.2023.1097574. eCollection 2023. Front Microbiol. 2023. PMID: 36970699 Free PMC article.
-
Overview of Complications in Cirrhosis.J Clin Exp Hepatol. 2022 Jul-Aug;12(4):1150-1174. doi: 10.1016/j.jceh.2022.04.021. Epub 2022 May 14. J Clin Exp Hepatol. 2022. PMID: 35814522 Free PMC article. Review.
-
Seroprevalence and prognostic value of Aspergillus-specific IgG among non-neutropenic invasive pulmonary aspergillosis patients: a prospective multicenter study.Pneumonia (Nathan). 2024 Nov 5;16(1):28. doi: 10.1186/s41479-024-00154-8. Pneumonia (Nathan). 2024. PMID: 39497226 Free PMC article.
-
Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005).Infection. 2025 Aug;53(4):1299-1310. doi: 10.1007/s15010-025-02572-2. Epub 2025 Jun 4. Infection. 2025. PMID: 40465080 Free PMC article. Review.
-
Influence of a Structured Microbiological Endotracheal Monitoring Program on the Outcome of Critically Ill COVID-19 Patients: An Observational Study.J Clin Med. 2023 Aug 28;12(17):5622. doi: 10.3390/jcm12175622. J Clin Med. 2023. PMID: 37685689 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical